Comparative Pharmacology
Head-to-head clinical analysis: AMICAR versus LYSTEDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMICAR versus LYSTEDA.
AMICAR vs LYSTEDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
Competitive inhibition of plasminogen activation, reducing fibrinolysis.
4-5 g IV loading dose over 1 hour, followed by 1 g/hour IV continuous infusion for 8 hours or until bleeding controlled; oral: 5 g PO initially, then 1-1.25 g PO every hour as needed.
650 mg orally three times daily (total 3.9 g/day) for up to 5 days during menses.
None Documented
None Documented
Terminal elimination half-life: 2 hours (range 1-3.5 hours). After high doses or renal impairment, half-life may prolong (up to 5-10 hours).
Terminal elimination half-life is approximately 2 hours (range 1.5–2.5 hours). In patients with renal impairment, half-life is significantly prolonged (up to 20 hours in severe renal impairment).
Renal: >99% of absorbed dose excreted unchanged in urine. Biliary/fecal: negligible (<1%).
Primarily renal excretion (>95% unchanged drug via glomerular filtration). Less than 5% is metabolized (mainly acylated derivative).
Category C
Category C
Antifibrinolytic
Antifibrinolytic